Rare ALS drug meets trial success goals
Columbia University researchers announced that an experimental drug for a rare ALS form met its primary endpoint in a major clinical trial.
A young woman named Jaci Hermstad received early access to the therapy before her death in 2020, providing crucial data on safety and effectiveness in humans. This case offered vital information regarding the drug's impact on brain tissue and protein levels.
For years, doctors could not identify the cause of ALS in most cases. But one to 2% of patients have mutations in the FUS gene causing the disease. Such mutations can be highly aggressive and often strike people in the prime of life.
The global FUSION trial began in 2021 and included seventy three patients who received either the investigational drug or a placebo over an eighteen month duration. Otsuka Pharmaceutical is now discussing expedited approval paths with regulators while an early access program remains open for eligible patients with confirmed genetic mutations.
Full results will be sent for publication in the near future. Data from twelve patients showed the therapy was safe and well tolerated. Some individuals regained significant motor function or prevented symptom development when treated early enough.

